Lavaca Capital’s Moderna MRNA Stock Holding History

Lavaca Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,000	Closed	-$880K	–	172
2023 Q1	$880K	Hold	5,000	–	–	0.18%	92
2022 Q4	$752K	Hold	5,000	–	–	0.23%	89
2022 Q3	$820K	Hold	5,000	–	–	0.29%	75
2022 Q2	$672K	Hold	5,000	–	–	0.1%	121
2022 Q1	$861K	Hold	5,000	–	–	0.09%	121
2021 Q4	$1.27M	Buy	+5,000	New	+$1.46M	0.16%	75

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lavaca Capital's MRNA Position: Q2 2023 in Review

Lavaca Capital sold out of Moderna (MRNA) in Q2 2023, closing a stake of 5,000 shares — an estimated $880K sold.

Lavaca Capital first reported a position in MRNA in Q4 2021 and held it in 6 quarters. The position peaked at $1.27M in Q4 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

Lavaca Capital reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
Lavaca Capital sold 5,000 Moderna shares in Q2 2023, an estimated $880K.
Lavaca Capital first reported a position in Moderna in Q4 2021 and held it in 6 quarters.
Lavaca Capital's Moderna position peaked at $1.27M in Q4 2021.
965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Lavaca Capital's 13F filing for Q2 2023, filed 15 Aug 2023.